Patients at high risk for metastatic disease, based on high plasma PSA, but with negative prostate biopsy or patients with rising PSA levels after local treatment with curative intent, undergo additional staging using computed tomography (CT), whole body magnetic resonance imaging (MRI), or 18F choline-based positron emission tomography (PET)/CT. Here, KLK3 is linked to metastatic neoplasm.